35 research outputs found
Undiagnosed mood disorders and sleep disturbances in primary care patients with chronic musculoskeletal pain.
Objective. The study aims to determine the prevalence
of undiagnosed comorbid mood disorders in
patients suffering chronic musculoskeletal pain in
a primary care setting and to identify sleep disturbances
and other associated factors in these
patients, and to compare the use of health services
by chronic musculoskeletal pain patients with and
without comorbid mood disorders.
Design. Cross-sectional study.
Subjects. A total of 1,006 patients with chronic musculoskeletal
pain from a representative sample of
primary care centers were evaluated.
Outcome Measures. Pain was measured using a
visual analog scale and the Primary Care Evaluation
of Mental Disorders questionnaire was used to
measure mood disorders.
Results. We observed a high prevalence of undiagnosed
mood disorders in chronic musculoskeletal
pain patients (74.7%, 95% confidence interval
[CI] 71.9–77.4%), with greater comorbidity in
women (adjusted odds ratio [OR] = 1.91, 95%
CI 1.37–2.66%) and widow(er)s (adjusted OR = 1.87,
95% CI 1.19–2.91%). Both sleep disturbances
(adjusted OR = 1.60, 95% CI 1.17–2.19%) and pain
intensity (adjusted OR = 1.02, 95% CI 1.01–1.02%)
displayed a direct relationship with mood disorders.
Moreover, we found that chronic musculoskeletal
pain patients with comorbid mood disorders availed
of health care services more frequently than those
without (P < 0.001).
Conclusions. The prevalence of undiagnosed mood
disorders in patients with chronic musculoskeletal
pain is very high in primary care settings. Our findings
suggest that greater attention should be paid to
this condition in general practice and that sleep disorders
should be evaluated in greater detail to
achieve accurate diagnoses and select the most
appropriate treatment
Activation of Extracellular Signal-Regulated Kinases (ERK 1/2) in the Locus Coeruleus Contributes to Pain-Related Anxiety in Arthritic Male Rats
Background: There is increasing evidence suggesting that the Locus Coeruleus plays a role in pain-related anxiety. Indeed, we previously found that prolonged arthritis produces anxiety-like behavior in rats, along with enhanced expression of phosphorylated extracellular signal-regulated kinase 1/2 (a marker of plasticity) in the Locus Coeruleus. However, it is unknown how this effect correlates with the electrophysiological activity of Locus Coeruleus neurons or pain-related anxiety.
Methods: Using the complete Freund's adjuvant model of monoarthritis in male Sprague-Dawley rats, we studied the behavioral attributes of pain and anxiety as well as Locus Coeruleus electrophysiology in vivo 1 (MA1W) and 4 weeks (MA4W) after disease induction.
Results: The manifestation of anxiety in MA4W was accompanied by dampened tonic Locus Coeruleus activity, which was coupled to an exacerbated evoked Locus Coeruleus response to noxious stimulation of the inflamed and healthy paw. When a mitogen-activating extracellular kinase inhibitor was administered to the contralateral Locus Coeruleus of MA4W, the phosphorylated extracellular signal-regulated kinase 1/2 levels in the Locus Coeruleus were restored and the exaggerated evoked response was blocked, reversing the anxiogenic-like behavior while pain hypersensitivity remained unaltered.
Conclusion: As phosphorylated extracellular signal-regulated kinase 1/2 blockade in the Locus Coeruleus relieved anxiety and counteracted altered LC function, we propose that phosphorylated extracellular signal-regulated kinase 1/2 activation in the Locus Coeruleus plays a crucial role in pain-related anxiety.This work was supported by the "Catedra Externa del Dolor Fundacion Grunenthal/Universidad de Cadiz," which paid a grant to the first author; the "Catedra em Medicina da Dor from Fundacao Grunenthal-Portugal and Faculdade de Medicina da Universidade do Porto"; co-financed by the Fondo Europeo de Desarrollo Regional "Una manera de hacer Europa" (PI13/02659); the "Ministerio de Economia y Competitividad", co-financed byFEDER (SAF2015-68647-R (MINECO/FEDER)); CIBERSAM G18; the "Consejeria de Economia, Innovacion, Ciencia y Empleo de la Junta de Andalucia", Seville, Spain (CTS-510 and Proyecto de Excelencia: CTS-7748); 2015 NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation; Fundacion Espanola de Dolor (travel fellowship granted to Gisela Borges - 1536); and Gobierno Vasco (IT747-13)
Pain and depression comorbidity causes asymmetric plasticity in the locus coeruleus neurons
There is strong comorbidity between chronic pain and depression, although the neural circuits and mechanisms underlying this association remain unclear. By combining immunohistochemistry, tracing studies and western blotting, with the use of different DREADDS (designer receptor exclusively activated by designer drugs) and behavioural approaches in a rat model of neuropathic pain (chronic constriction injury), we explore how this comorbidity arises. To this end, we evaluated the time-dependent plasticity of noradrenergic locus coeruleus neurons relative to the site of injury: ipsilateral (LCipsi) or contralateral (LCcontra) locus coeruleus at three different time points: short (2 days), mid (7 days) and long term (30-35 days from nerve injury). Nerve injury led to sensorial hypersensitivity from the onset of injury, whereas depressive-like behaviour was only evident following long-term pain. Global chemogenetic blockade of the LCipsi system alone increased short-term pain sensitivity while the blockade of the LCipsi or LCcontra relieved pain-induced depression. The asymmetric contribution of locus coeruleus modules was also evident as neuropathy develops. Hence, chemogenetic blockade of the LCipsi -> spinal cord projection, increased pain-related behaviours in the short term. However, this lateralized circuit is not universal as the bilateral chemogenetic inactivation of the locus coeruleus-rostral anterior cingulate cortex pathway or the intra-rostral anterior cingulate cortex antagonism of alpha1- and alpha2-adrenoreceptors reversed long-term pain-induced depression. Furthermore, chemogenetic locus coeruleus to spinal cord activation, mainly through LCipsi, reduced sensorial hypersensitivity irrespective of the time post-injury. Our results indicate that asymmetric activation of specific locus coeruleus modules promotes early restorative analgesia, as well as late depressive-like behaviour in chronic pain and depression comorbidity.Peer reviewe
Fluoxetine: a case history of its discovery and preclinical development
Introduction: Depression is a multifactorial mood disorder with a high prevalence worldwide. Until now, treatments for depression have focused on the inhibition of monoaminergic reuptake sites, which augment the bioavailability of monoamines in the CNS. Advances in drug discovery have widened the therapeutic options with the synthesis of so-called selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine.
Areas covered: The aim of this case history is to describe and discuss the pharmacokinetic and pharmacodynamic profiles of fluoxetine, including its acute effects and the adaptive changes induced after long-term treatment.
Furthermore, the authors review the effect of fluoxetine on neuroplasticity and adult neurogenesis. In addition, the article summarises the preclinical behavioural data available on fluoxetine’s effects on depressive-like behaviour,
anxiety and cognition as well as its effects on other diseases. Finally, the article describes the seminal studies validating the antidepressant effects of fluoxetine.
Expert opinion: Fluoxetine is the first selective SSRI that has a recognised clinical efficacy and safety profile. Since its discovery, other molecules that mimic its mechanism of action have been developed, commencing a new
age in the treatment of depression. Fluoxetine has also demonstrated utility in the treatment of other disorders for which its prescription has now been approved
T cells with dysfunctional mitochondria induce multimorbidity and premature senescence
The effect of immunometabolism on age-associated diseases remains uncertain. In this work, we show that T cells with dysfunctional mitochondria owing to mitochondrial transcription factor A (TFAM) deficiency act as accelerators of senescence. In mice, these cells instigate multiple aging-related features, including metabolic, cognitive, physical, and cardiovascular alterations, which together result in premature death. T cell metabolic failure induces the accumulation of circulating cytokines, which resembles the chronic inflammation that is characteristic of aging (“inflammaging”). This cytokine storm itself acts as a systemic inducer of senescence. Blocking tumor necrosis factor-a signaling or preventing senescence with nicotinamide adenine dinucleotide precursors partially rescues premature aging in mice with Tfam-deficient T cells. Thus, T cells can regulate organismal fitness and life span, which highlights the importance of tight immunometabolic control in both aging and the onset of age-associated diseases.This study was supported by the Fondo de Investigación Sanitaria del Instituto de Salud Carlos III (PI16/02188 and PI19/00855; and PI16/02110 to B.I.), the European Regional Development Fund (ERDF), and the European Commission through H2020-EU.1.1 and European Research Council grant ERC-2016-StG 715322-EndoMitTalk. This work was partially supported by Comunidad de Madrid (S2017/BMD-3867 RENIM-CM). M.M. is supported by the Miguel Servet Program (CPII 19/00014). G.S.-H. is supported by FPI-UAM, J.O. (FJCI-2017-33855) and E.G.-R. (IJC2018-036850) by Juan de la Cierva, and E.C. by Atracción de Talento Investigador 2017-T2/BMD-5766 (Comunidad de Madrid and UAM). B.I. was supported by ERC research grant ERC-2018-CoG 819775-MATRIX
Medically unexplained pain complaints are associated with underlying unrecognized mood disorders in primary care
<p>Abstract</p> <p>Background</p> <p>Patients with chronic pain frequently display comorbid depression, but the impact of this concurrence is often underestimated and mistreated. The aim of this study was to determine the prevalence of unrecognized major depression and other mood disorders and comorbid unexplained chronic pain in primary care settings and to explore the associated factors.</p> <p>Also, to compare the use of health services by patients with unexplained chronic pain, both with and without mood disorder comorbidity.</p> <p>Methods</p> <p>A cross-sectional study was carried out in a sample of primary care centers. 3189 patients consulting for "unexplained chronic pain" were assessed by the Visual Analogue Scales (VAS) and the Primary Care Evaluation of Mental Disorders (PRIME-MD) questionnaire.</p> <p>Results</p> <p>We report: a) a high prevalence of unrecognized mood disorders in patients suffering from unexplained chronic pain complaints (80.4%: CI 95%: 79.0%; 81.8%); b) a greater susceptibility of women to mood disorders (OR adjusted = 1.48; CI 95%:1.22; 1.81); c) a direct relationship between the prevalence of mood disorders and the duration of pain (OR adjusted = 1.01; CI 95%: 1.01; 1.02) d) a higher comorbidity with depression if the pain etiology was unknown (OR adjusted = 1.74; CI 95%: 1.45; 2.10) and, e) an increased use of health care services in patients with such a comorbidity (p < 0.0001).</p> <p>Conclusions</p> <p>The prevalence of undiagnosed mood disorders in patients with unexplained chronic pain in primary care is very high, leading to dissatisfaction with treatment processes and poorer outcomes. Consequently, it seems necessary to explore this condition more regularly in general practice in order to reach accurate diagnoses and to select the appropriate treatment.</p
Monoamines as Drug Targets in Chronic Pain: Focusing on Neuropathic Pain
Monoamines are involved in regulating the endogenous pain system and indeed,
peripheral and central monoaminergic dysfunction has been demonstrated in certain
types of pain, particularly in neuropathic pain. Accordingly, drugs that modulate the
monaminergic system and that were originally designed to treat depression are now
considered to be first line treatments for certain types of neuropathic pain (e.g., serotonin
and noradrenaline (and also dopamine) reuptake inhibitors). The analgesia induced by
these drugs seems to be mediated by inhibiting the reuptake of these monoamines,
thereby reinforcing the descending inhibitory pain pathways. Hence, it is of particular
interest to study the monoaminergic mechanisms involved in the development and
maintenance of chronic pain. Other analgesic drugs may also be used in combination
with monoamines to facilitate descending pain inhibition (e.g., gabapentinoids and
opioids) and such combinations are often also used to alleviate certain types of
chronic pain. By contrast, while NSAIDs are thought to influence the monoaminergic
system, they just produce consistent analgesia in inflammatory pain. Thus, in this
review we will provide preclinical and clinical evidence of the role of monoamines in
the modulation of chronic pain, reviewing how this system is implicated in the analgesic
mechanism of action of antidepressants, gabapentinoids, atypical opioids, NSAIDs and
histaminergic drug
In Vivo Effect of Venlafaxine on Locus Coeruleus Neurons: Role of Opioid, ␣ 2 -Adrenergic, and 5-Hydroxytryptamine 1A Receptors
ABSTRACT The locus coeruleus (LC) is involved in several neural pathways responsible for some somatic and emotional processes, such as pain and depression; its activity is regulated by several receptors, such as opioid, ␣ 2 -adrenergic, and 5-hydroxytryptamine (5-HT) 1A receptors. The present study investigates the in vivo effects of venlafaxine, an antidepressant with analgesic properties, on locus coeruleus neurons, and its modulation by opioid, ␣ 2 -adrenergic, and 5-HT 1A receptors. The results show that acute administration of venlafaxine produced a dose-dependent, complete inhibition of LC activity. This inhibitory effect was not reversed by the opioid receptor antagonist naloxone, but subsequent administration of idazoxan, an ␣ 2 -adrenoceptor antagonist, did reverse it. The preadministration of the 5-HT 1A receptor agonist 8-hydroxy-2-dipropylaminotetralin (8-OH-DPAT) (1 and 40 g/kg) significantly enhanced the venlafaxine inhibitory effect, decreasing the ED 50 by 56 and 44%, respectively. A 14-day treatment with venlafaxine (40 mg/kg/ day) induced a suppression of the firing activity of LC neurons. In these treated animals, venlafaxine produced an inhibitory effect similar to that in nontreated animals. This inhibitory effect was not reversed by naloxone, but it was reversed by idazoxan. In addition, the preadministration of 8-OH-DPAT (40 g/kg) significantly enhanced the venlafaxine effect, decreasing the ED 50 by 60%. These results suggest that the effect of venlafaxine on LC neurons is modulated by ␣ 2 -adrenergic and 5-HT 1A receptors, and not by opioid receptors. These data could contribute to the further understanding of the antidepressant and analgesic mechanism of action of venlafaxine. Venlafaxine is a dual 5-hydroxytryptamine (serotonin)/ noradrenaline (5-HT/NA) reuptake inhibitor (SNRI) antidepressant that blocks the synaptosomal uptake of 5-HT at low doses and NA at higher dose